Rosen Sydney, Fox Matthew P, Gill Christopher J
Center for International Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America.
PLoS Med. 2007 Oct 16;4(10):e298. doi: 10.1371/journal.pmed.0040298.
Long-term retention of patients in Africa's rapidly expanding antiretroviral therapy (ART) programs for HIV/AIDS is essential for these programs' success but has received relatively little attention. In this paper we present a systematic review of patient retention in ART programs in sub-Saharan Africa.
We searched Medline, other literature databases, conference abstracts, publications archives, and the "gray literature" (project reports available online) between 2000 and 2007 for reports on the proportion of adult patients retained (i.e., remaining in care and on ART) after 6 mo or longer in sub-Saharan African, non-research ART programs, with and without donor support. Estimated retention rates at 6, 12, and 24 mo were calculated and plotted for each program. Retention was also estimated using Kaplan-Meier curves. In sensitivity analyses we considered best-case, worst-case, and midpoint scenarios for retention at 2 y; the best-case scenario assumed no further attrition beyond that reported, while the worst-case scenario assumed that attrition would continue in a linear fashion. We reviewed 32 publications reporting on 33 patient cohorts (74,192 patients, 13 countries). For all studies, the weighted average follow-up period reported was 9.9 mo, after which 77.5% of patients were retained. Loss to follow-up and death accounted for 56% and 40% of attrition, respectively. Weighted mean retention rates as reported were 79.1%, 75.0% and 61.6 % at 6, 12, and 24 mo, respectively. Of those reporting 24 mo of follow-up, the best program retained 85% of patients and the worst retained 46%. Attrition was higher in studies with shorter reporting periods, leading to monthly weighted mean attrition rates of 3.3%/mo, 1.9%/mo, and 1.6%/month for studies reporting to 6, 12, and 24 months, respectively, and suggesting that overall patient retention may be overestimated in the published reports. In sensitivity analyses, estimated retention rates ranged from 24% in the worse case to 77% in the best case at the end of 2 y, with a plausible midpoint scenario of 50%.
Since the inception of large-scale ART access early in this decade, ART programs in Africa have retained about 60% of their patients at the end of 2 y. Loss to follow-up is the major cause of attrition, followed by death. Better patient tracing procedures, better understanding of loss to follow-up, and earlier initiation of ART to reduce mortality are needed if retention is to be improved. Retention varies widely across programs, and programs that have achieved higher retention rates can serve as models for future improvements.
在非洲迅速扩大的抗逆转录病毒疗法(ART)项目中,让患者长期接受治疗对于这些项目的成功至关重要,但这方面受到的关注相对较少。在本文中,我们对撒哈拉以南非洲地区ART项目中的患者留存情况进行了系统综述。
我们检索了2000年至2007年间的医学期刊数据库(Medline)、其他文献数据库、会议摘要、出版物存档以及“灰色文献”(可在线获取的项目报告),以查找有关撒哈拉以南非洲地区非研究性ART项目中成年患者在接受治疗6个月或更长时间后仍留存(即继续接受治疗并使用ART)比例的报告,这些项目有或没有捐赠者支持。计算并绘制了每个项目在6个月、12个月和24个月时的估计留存率。还使用Kaplan-Meier曲线估计留存情况。在敏感性分析中,我们考虑了2年留存情况的最佳情况、最差情况和中点情况;最佳情况假设除已报告的流失情况外不再有其他流失,而最差情况假设流失将以线性方式持续。我们审查了32篇报告33个患者队列(74192名患者,13个国家)的出版物。对于所有研究,报告的加权平均随访期为9.9个月,之后77.5%的患者仍在接受治疗。失访和死亡分别占流失的56%和40%。报告的加权平均留存率在6个月、12个月和24个月时分别为79.1%、75.0%和61.6%。在报告24个月随访情况的研究中,表现最佳的项目留存了85%的患者,最差的留存了46%。报告期较短的研究中的流失率较高,导致报告至6个月、12个月和24个月的研究的每月加权平均流失率分别为3.3%/月、1.9%/月和1.6%/月,这表明已发表报告中对总体患者留存情况可能估计过高。在敏感性分析中,2年结束时的估计留存率在最差情况下为24%,最佳情况下为77%,合理的中点情况为50%。
自本世纪初大规模提供ART以来,非洲的ART项目在2年结束时约留住了60%的患者。失访是流失的主要原因,其次是死亡。若要提高留存率,需要更好的患者追踪程序、对失访情况的更好理解以及更早开始ART以降低死亡率。各项目的留存情况差异很大,实现了较高留存率的项目可作为未来改进的典范。